Flagship Pioneering related stories
All articles and analysis
MPM Capital adds new MD to teamMPM Capital named Gregory Sieczkiewicz as managing director and chief counsel, intellectual property. The appointment is effective immediately. Previously, Sieczkiewicz worked at Flagship Ventures where he served as vice president of intellectual property.
- Flagship Ventures to back Red Rock Biofuels
Flagship Ventures has agreed to invest in Red Rock BioFuels LLC. No financial terms were disclosed. Also, Flagship Ventures will take a seat on Red Rock's board of directors. Based in Fort Collins, Colorado, Red Rock Biofuels is a provider of renewable biofuels.
- Blend Therapeutics scores $21 mln
Watertown, Mass.-based Blend Therapeutics, a biopharmaceutical firm focused on treating cancer, has raised $21 million in funding. Blend's investors include New Enterprise Associates, Flagship Ventures, NanoDimension and Eminent Venture Capital.
- Flagship And Updata target fifth funds
Flagship Ventures and Updata Partners are both raising fifth funds, according to a pair of filings with the Securities and Exchange Commission.
- VC-backed Acceleron Pharma adds to board of directors
Acceleron Pharma has appointed Dr. Francois Nader to its board of directors. Nader is president, CEO and a member of the board of directors of NPS Pharma. Acceleron Pharma's backers include Advanced Technology Ventures, Flagship Ventures, OrbiMed Advisors, Polaris Ventures and Venrock. Based in Cambridge, Mass., Acceleron is focused on developing novel protein therapeutics for cancer and rare diseases.
- Seres Health fetches $48 mln
Seres Health has raised $48 million in Series C funding. The investors in this round were not named; however, the firm was seeded by Flagship Ventures. Based in Cambridge, Mass., Seres Health is a biotherapeutic company focused on developing drugs that target the human microbiome.
- Flagship Ventures backs Symbiota
Symbiota has closed $7.5 million in Series A funding from Flagship Ventures. Based in Cambridge, Mass., Symbiota is a provider of microbial solutions.
- Paine & Partners adds new operating director to team
Paine & Partners has hired Robert Berendes as an operating director. Berendes is currently a venture partner at Flagship Ventures.
- Selecta Biosciences raises $20 million
Selecta Biosciences said Wednesday it has secured $20 million in equity funding from new and all of Selecta’s existing investors. Including the $20 million, Selecta said it has obtained a total of $78.6 Million in funding to date. Investors include Polaris Venture Partners, Flagship Ventures, OrbiMed Advisors, NanoDimension, Rusnano, I2BF, Eminent Venture Capital and Leukon Investments. Selecta is a clinical stage biotechnology company that is developing a class of targeted antigen-specific immune therapies.
IPO Profile: T2 Biosystems IncInvestors, including Aisling, Flagship, Flybridge and others, put more than $99 million into the company